The effect of fluconazole on the pharmacokinetics of rosuvastatin

European Journal of Clinical Pharmacology

Volumn 58, Issue 8, 2002, Pages 527-531

  Cooper, K J ^a   Martin, P D ^a   Dane, A L ^a   Warwick, M J ^a   Schneck, D W ^a   Cantarini, Mireille V ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CYP2C19; CYP2C9; Fluconazole; Pharmacokinetics; Rosuvastatin

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DRUG METABOLITE; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; MEASUREMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FLUCONAZOLE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES;

EID: 0036451138     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0508-8     Document Type: Article

References (9)

1. Olsson AG, Pears J, McKellar J, Mizan J, Raza A (2001) Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 88:504-508
2. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H (2002) Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 89:268-275
3. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ (2002) No effect of age or gender on the pharmacokinetics of rosuvastatin - A new HMG-CoA reductase inhibitor. J Clin Pharmacol 42:1116-1121
4. Martin PD, Dane AL, Schneck DW, Warwick MJ (2000) Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects (abstract 48). J Clin Pharmacol 40:1056
5. McCormick AD, McKillop D, Butters CJ, Miles GS, Baba T, Touchi A, Yamaguchi Y (2000) ZD4522 - An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems (abstract 46). J Clin Pharmacol 40:1055
6. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF (1996) Warfarin-fluconazole. II. A metabolically based drug interaction: In vivo studies. Drug Metab Dispos 24:422-428
7. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ (2000) Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 56:225-229
8. Hull CK, Penman AD, Smith CK, Martin PD (2002) Quanti-fication of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection. J Chromatogr B Biomed Appl 772:219-228
9. Tucker GT, Houston JB, Huang S-M (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - Toward a consensus. Clin Pharmacol Ther 70:103-114